ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' - iShares Core S&P Small-Cap ETF (ARCA:IJR), ServiceNow (NYSE:NOW)

Group 1: ServiceNow, Inc. - Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, expressed a favorable view on ServiceNow, Inc. (NYSE:NOW), noting a year-to-date decline of 14% in its stock price [1] - Morgan Stanley analyst Keith Weiss upgraded ServiceNow from Equal-Weight to Overweight on September 24, increasing the price target from $1,040 to $1,250 [1] Group 2: Vertex Pharmaceuticals Inc - Jim Lebenthal, partner at Cerity Partners, highlighted Vertex Pharmaceuticals Inc (NASDAQ:VRTX) for its strong drug profile [2] - Citigroup analyst Geoff Meacham maintained a Buy rating for Vertex Pharmaceuticals on October 2, raising the price target from $550 to $575 [3] - Vertex Pharmaceuticals received FDA Breakthrough designation for Povetacicept in IgAN, completed AMKD trial enrollment, and launched an ADPKD study, aiming for first-in-class kidney therapies [3] Group 3: iShares Core S&P Small-Cap ETF - Shannon Saccocia, chief investment officer of NB Private Wealth, identified iShares Core S&P Small-Cap ETF (NYSE:IJR) as her final trade [1]